Home / Health / Merck's Pneumococcal Vaccine Bolsters Immunity in High-Risk Youth
Merck's Pneumococcal Vaccine Bolsters Immunity in High-Risk Youth
11 Sep
Summary
- Merck's pneumococcal shot showed strong immune responses in children and teens at higher risk of serious illness
- Results presented at a vaccines meeting in Lisbon last month
- Vaccine targets a leading cause of pneumonia, meningitis, and other serious infections
Last month, pharmaceutical giant Merck announced promising results from a late-stage study of its pneumococcal vaccine. The findings, presented at a vaccines conference in Lisbon, indicate the shot has elicited strong immune responses in children and teenagers who are at higher risk of developing serious illnesses.
Pneumococcal disease, caused by the Streptococcus pneumoniae bacteria, is a leading cause of pneumonia, meningitis, and other life-threatening infections. Merck's vaccine targets this common pathogen, offering hope of better protection for vulnerable populations.
According to the report, the vaccine demonstrated robust immune responses in the clinical trial participants, who included children and adolescents considered to be at elevated risk of contracting pneumococcal disease. This suggests the shot could be an effective tool in safeguarding the health of these high-risk groups against a serious and potentially deadly illness.
